Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
Appetite suppression is one of the most common side effects of methylphenidate (MPH), which is used for treatment of attention-deficit hyperactivity disorder (ADHD). Relation of appetite and leptin is well known but there is no report regarding MPH use and leptin. In this study we compared the baseline leptin levels of ADHD children with the controls and studied the interaction between MPH and leptin-insulin level in ADHD children under MPH treatment. The major finding of this study is that at a total daily dose of 0.6 mg/kg short-acting MPH treatment, one does not observe significant side effects related to appetite suppression and metabolic features as measured via body mass index, insulin and leptin levels. Thus this range seems to be safe in developing ADHD children with minimum side effects regarding appetite for short-term treatment.
Işeri
E
E
Department of Child and Adolescent Psychiatry, Gazi University School of Medicine, Ankara, Turkey. ekaracan@gazi.edu.tr
Kiliç
B G
BG
Senol
S
S
Karabacak
N I
NI
D001066:Appetite / Q000187:drug effects*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D015992:Body Mass Index; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007328:Insulin / Q000097:blood*; D020738:Leptin / Q000378:metabolism*; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
D000697:Central Nervous System Stimulants; D007328:Insulin; D020738:Leptin; D008774:Methylphenidate